BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 24085241)

  • 21. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.
    Vij R; Kumar S; Zhang MJ; Zhong X; Huang J; Dispenzieri A; Abidi MH; Bird JM; Freytes CO; Gale RP; Kindwall-Keller TL; Kyle RA; Landsburg DJ; Lazarus HM; Munker R; Roy V; Sharma M; Vogl DT; Wirk B; Hari PN
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):335-41. PubMed ID: 25445028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controversies in multiple myeloma: to transplant or not?
    Preeshagul IR; Van Besien K; Mark TM
    Curr Hematol Malig Rep; 2014 Dec; 9(4):360-7. PubMed ID: 25145553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
    Ahn SY; Jung SH; Joo YD; Lee WS; Lee SM; Choi CW; Kim SJ; Kim K; Lee JJ;
    Ann Hematol; 2014 Sep; 93(9):1571-7. PubMed ID: 24728664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
    Lee JH; Lee JH; Kim DY; Kim SD; Choi Y; Kang YA; Seol M; Lee KH
    Eur J Haematol; 2012 Jun; 88(6):478-84. PubMed ID: 22364526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma.
    Lee SE; Yoon JH; Shin SH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Min CK
    Ann Hematol; 2014 Apr; 93(4):627-34. PubMed ID: 24085241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrating novel therapies in the transplant paradigm.
    Harousseau JL
    Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of consolidation therapy in transplant eligible multiple myeloma patients.
    Cavo M; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Zamagni E
    Semin Oncol; 2013 Oct; 40(5):610-7. PubMed ID: 24135406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.